Skip to main content

Growth Disorder

2
Pipeline Programs
4
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
Treatment with Genotropin in different dosagesPhase 31 trial
Active Trials
NCT00174421Completed36Est. Aug 2005
Prevail Therapeutics
1 program
1
somatropin, rDNA origin, for injectionPhase 31 trial
Active Trials
NCT00191074Completed11Est. Jan 2006
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
5 programs
No treatment givenN/A1 trial
somatropinN/A1 trial
Norditropin® FlexPro® penPHASE_11 trial
somatropinPHASE_11 trial
somatropinPHASE_31 trial
Active Trials
NCT02580032Completed252Est. May 2018
NCT01578135Completed291Est. Oct 2018
NCT01943084Completed32Est. Oct 2013
+2 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
somatropin, rDNA origin, for injectionPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo Nordisksomatropin
PfizerTreatment with Genotropin in different dosages
Prevail Therapeuticssomatropin, rDNA origin, for injection
Novo NordiskNorditropin® FlexPro® pen
Novo Nordisksomatropin
Novo NordiskNo treatment given
Novo Nordisksomatropin

Clinical Trials (7)

Total enrollment: 676 patients across 7 trials

NCT01778023Novo Nordisksomatropin

Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature

Start: Jan 2013Est. completion: Dec 201454 patients
Phase 3Completed
NCT00174421PfizerTreatment with Genotropin in different dosages

Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height

Start: Apr 2001Est. completion: Aug 200536 patients
Phase 3Completed
NCT00191074Prevail Therapeuticssomatropin, rDNA origin, for injection

Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature

Start: Feb 2001Est. completion: Jan 200611 patients
Phase 3Completed
NCT01943084Novo NordiskNorditropin® FlexPro® pen

A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

Start: Sep 2013Est. completion: Oct 201332 patients
Phase 1Completed
NCT01512095Novo Nordisksomatropin

Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers

Start: Aug 2013Est. completion: Nov 20130
Phase 1Withdrawn
NCT02580032Novo NordiskNo treatment given

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

Start: Oct 2015Est. completion: May 2018252 patients
N/ACompleted
NCT01578135Novo Nordisksomatropin

French National Registry of Children Born Small for Gestational Age Treated With Somatropin

Start: Mar 2007Est. completion: Oct 2018291 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.